Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition
2015 · Nature Communications · 284 citations
https://doi.org/10.1038/ncomms7139
A
Aaron Goldman
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
91
Papers
2.1K
Citations
26
h-index
39
i10-index
Aaron Goldman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers & Cancer Cells and Metastasis. The author has an h-index of 26, co-authored 78 publications.
ORCID: 0000-0002-9129-1311Papers by this author
worksAdvances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
2021 · Drug Discovery Today · 169 citations
https://doi.org/10.1016/j.drudis.2021.09.020
Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects
2016 · Scientific Reports · 46 citations
https://doi.org/10.1038/srep27439
Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting
2021 · JAMA Network Open · 45 citations
https://doi.org/10.1001/jamanetworkopen.2021.10446
Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice
2023 · Cell Reports Medicine · 30 citations
https://doi.org/10.1016/j.xcrm.2023.100957
Controlled tumor heterogeneity in a co-culture system by 3D bio-printed tumor-on-chip model
2023 · Scientific Reports · 28 citations
https://doi.org/10.1038/s41598-023-40680-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat